Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269453 | 0.94 | ALDH1A1 (0.36) | ALDH1A1PIK3CDKMT2AKDM4EGBA1 | |
| SCHEMBL31269166 | 0.93 | ALDH1A1 (0.40) | ALDH1A1PIK3CDKMT2AKDM4EGBA1 | |
| SCHEMBL31269392 | 0.90 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL31268837 | 0.90 | KDM4E (0.33) | ALDH1A1PIK3CDKDM4ECNR1 | |
| SCHEMBL31268824 | 0.90 | PIK3CD (0.34) | ALDH1A1PIK3CDLMNA | |
| SCHEMBL31269011 | 0.89 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL31269460 | 0.89 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL31268842 | 0.89 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL31269027 | 0.89 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL31269189 | 0.88 | HRH4 (0.33) | PIK3CDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |